WO2016138182A1 - Méthodes et compositions d'immunomodulation - Google Patents

Méthodes et compositions d'immunomodulation Download PDF

Info

Publication number
WO2016138182A1
WO2016138182A1 PCT/US2016/019423 US2016019423W WO2016138182A1 WO 2016138182 A1 WO2016138182 A1 WO 2016138182A1 US 2016019423 W US2016019423 W US 2016019423W WO 2016138182 A1 WO2016138182 A1 WO 2016138182A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
sample
treatment
immune
Prior art date
Application number
PCT/US2016/019423
Other languages
English (en)
Inventor
Drew Hotson
Andy CONROY
Erwan LE SCOLAN
Rachael HAWTIN
Original Assignee
Nodality, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nodality, Inc. filed Critical Nodality, Inc.
Publication of WO2016138182A1 publication Critical patent/WO2016138182A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'immunomodulation de cellules et la détection et l'utilisation associées, par exemple, dans le criblage de médicaments, notamment des méthodes, des compositions et des systèmes s'y rapportant, ou dans un aspect relatif aux soins de santé, tel que le pronostic, le diagnostic, un aspect de traitement, de surveillance, et analogue, ainsi que des méthodes, des compositions, et des systèmes à cet effet.
PCT/US2016/019423 2015-02-24 2016-02-24 Méthodes et compositions d'immunomodulation WO2016138182A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562120217P 2015-02-24 2015-02-24
US62/120,217 2015-02-24
US201562192956P 2015-07-15 2015-07-15
US62/192,956 2015-07-15
US201562242901P 2015-10-16 2015-10-16
US62/242,901 2015-10-16
US201662295999P 2016-02-16 2016-02-16
US62/295,999 2016-02-16

Publications (1)

Publication Number Publication Date
WO2016138182A1 true WO2016138182A1 (fr) 2016-09-01

Family

ID=56789846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/019423 WO2016138182A1 (fr) 2015-02-24 2016-02-24 Méthodes et compositions d'immunomodulation

Country Status (1)

Country Link
WO (1) WO2016138182A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023624A1 (fr) * 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Biomarqueur sanguin périphérique prédictif pour inhibiteurs de points de contrôle
CN113201481A (zh) * 2021-04-19 2021-08-03 清华大学深圳国际研究生院 皮肤微球及其制备方法和应用
WO2023081243A1 (fr) * 2021-11-03 2023-05-11 Toreador Therapeutics, Inc. Procédés et systèmes pour l'étude à super-résolution de thérapies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244133A1 (en) * 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20130309250A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20140127716A1 (en) * 2009-09-08 2014-05-08 Nodality, Inc Benchmarks for normal cell identification
US20140147857A1 (en) * 2008-07-10 2014-05-29 Nodality, Inc. Methods for diagnosis prognosis and methods of treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140147857A1 (en) * 2008-07-10 2014-05-29 Nodality, Inc. Methods for diagnosis prognosis and methods of treatment
US20140127716A1 (en) * 2009-09-08 2014-05-08 Nodality, Inc Benchmarks for normal cell identification
US20120244133A1 (en) * 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20130309250A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BANER ET AL.: "Analysis of T- Cell Receptor V Gene Repertoires after Immune Stimulation and in Malignancy by Use of Padlock Probes and Microarrays", CLINICAL CHEMISTRY, vol. 51, 1 April 2005 (2005-04-01), pages 768 - 775, XP002423151, DOI: doi:10.1373/clinchem.2004.047266 *
GALON ET AL.: "The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures", IMMUNITY, vol. 39, 25 July 2013 (2013-07-25), pages 11 - 26, XP055234918, DOI: doi:10.1016/j.immuni.2013.07.008 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023624A1 (fr) * 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Biomarqueur sanguin périphérique prédictif pour inhibiteurs de points de contrôle
US11899017B2 (en) 2017-07-28 2024-02-13 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
CN113201481A (zh) * 2021-04-19 2021-08-03 清华大学深圳国际研究生院 皮肤微球及其制备方法和应用
CN113201481B (zh) * 2021-04-19 2023-10-13 清华大学深圳国际研究生院 皮肤微球及其制备方法和应用
WO2023081243A1 (fr) * 2021-11-03 2023-05-11 Toreador Therapeutics, Inc. Procédés et systèmes pour l'étude à super-résolution de thérapies

Similar Documents

Publication Publication Date Title
US20170370933A1 (en) Methods and compositions for immunomodulation
US8273544B2 (en) Methods for diagnosis, prognosis and methods of treatment
US20170285027A1 (en) Methods for diagnosis, prognosis and methods of treatment
US8778620B2 (en) Methods for diagnosis, prognosis and methods of treatment
US20140199273A1 (en) Methods for diagnosis, prognosis and methods of treatment
US20100099109A1 (en) Methods for Analyzing Drug Response
US20170292946A1 (en) Methods for diagnosis, prognosis and methods of treatment
US20170184594A1 (en) Pathway characterization of cells
US20170363633A1 (en) Methods for diagnosis, prognosis and methods of treatment
EP2580352A2 (fr) Caractérisation de voies de cellules
US20130035253A1 (en) Methods for diagnosis, prognosis and methods of treatment
WO2012024546A2 (fr) Incorporation de mesures de l'état de santé dans l'analyse et l'interprétation de données de réponse biologique fonctionnelle
WO2016138182A1 (fr) Méthodes et compositions d'immunomodulation
WO2014081987A1 (fr) Procédés de diagnostic et de pronostic, et procédés de traitement
WO2016036878A1 (fr) Procédés de diagnostic, de pronostic et procédés de traitement
GB2474777A (en) Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16756314

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09.02.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16756314

Country of ref document: EP

Kind code of ref document: A1